Show simple item record

dc.contributorSociedad Médica de Santiagoes_CL
dc.contributor.authorMontero, Julio C [Argentina.Universidad Nacl Buenos Aires]es_CL
dc.contributor.authorSaavedra-Gajardo, Víctor [Chile. Universidad Mayor]es_CL
dc.contributor.authorCerda-Flores, Ricardo [México. Instituto Mexicano del Seguro Social]es_CL
dc.date.accessioned2018-09-07T14:11:53Z
dc.date.available2018-09-07T14:11:53Z
dc.date.issued2008es_CL
dc.identifier.citationBastarrachea Raúl A, Montero Julio C, Saavedra-Gajardo íctor, Cerda-Flores Ricardo, Machado-Domínguez Anselmo, Comuzzie Anthony G. Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad. Rev. méd. Chile [Internet]. 2008 Ene [citado 2018 Ago 23] ; 136( 1 ): 107-117. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000100014&lng=es. http://dx.doi.org/10.4067/S0034-98872008000100014.es_CL
dc.identifier.issnISSN 0034-9887es_CL
dc.identifier.urihttps://scielo.conicyt.cl/pdf/rmc/v136n1/art14.pdfes_CL
dc.identifier.urihttp://dx.doi.org/10.4067/S0034-98872008000100014es_CL
dc.identifier.urihttp://repositorio.umayor.cl/xmlui/handle/sibum/2858
dc.description.abstractCurrent strategies to treat type 2 diabetes (DMT2) include reducing insulin resistance using glitazones, supplementing with exogenous insulin, increasing endogenous insulin production with sulfonylureas and meglitinides, reducing hepatic glucose production through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors. In all of these areas, new generations of molecules with improved efficacy and safety profiles, are being investigated. Promising biological targets are rapidly emerging such as the role of lipotoxicity as a cause of glucometabolic insulin resistance, leading to a host of new molecular drug targets such as AMP-activated protein kinase (AMPK) activators, recombinant adiponectin derivatives, and fatty acid synthase (FAS) inhibitors. Insulin action can be enhanced in muscle, liver and fat, with small-molecule activators of the insulin receptor or inhibitors of protein tyrosine phosphatase (FTP)-IB. Defective glucose-stimulated insulin secretion by pancreatic B-cells could be alleviated with recombinant glucagon-like peptide (GLP-1) or agonists to the GLP-1 receptor. This review presents a new approach for obesity and DMT2 drug discovery through pharmacogenomics. Several compounds have already been validated through genetic engineering in animal models or the preliminary use of therapeutic compounds in humans.es_CL
dc.description.sponsorshipEste trabajo no contó con financiamiento.es_CL
dc.format.extentREVISIÓNes_CL
dc.language.isoeses_CL
dc.publisherCIENCIASes_CL
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chilees_CL
dc.subjectMEDICINA INTERNAes_CL
dc.titleObjetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidades_CL
dc.title.alternativeMolecular targets for new drug discovery to treat type 2 diabetes and obesity.es_CL
dc.typeArtículo o Paperes_CL
umayor.indizadorCOTes_CL
umayor.politicas.sherpa/romeoLicencia color: VERDE (Revista Scielo)--Licencia creative commons BY // Disponible en: www.scielo.cles_CL
umayor.indexadoWOSes_CL
umayor.indexadoSCOPUSes_CL
umayor.indexadoSCIELOes_CL
dc.identifier.doi10.4067/S0034-98872008000100014es_CL]
umayor.indicadores.wos-(cuartil)Q3es_CL
umayor.indicadores.scopus-(scimago-sjr)0.26es_CL


Show simple item record